An Open-label Multi-center Single Agent Panobinostat Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Panobinostat Study and Are Judged by the Investigator to Benefit From Continued Single Agent Panobinostat Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 May 2019
At a glance
- Drugs Panobinostat (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 May 2019 This trial has been completed in Netherlands.
- 02 Feb 2019 The trial has been completed in the Spain, according to European Clinical Trials Database.
- 29 Jan 2019 Planned End Date changed from 22 Nov 2018 to 28 Feb 2019.